Kisqali is an oral drug that serves as a first-line treatment for post menopausal women with breast cancer when used in combination with letrozole, another type of breast cancer drug.
The drug slows cancer progression by limiting the over-activation of two proteins that can cause cancer cells to grow and divide too quickly, according to a news release.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.